HER2-Positive Breast Cancer Patients Prefer Subcutaneous Trastuzumab

Results of the PrefHer study indicated that when given the option between subcutaneous trastuzumab and intravenous trastuzumab, significantly more patients with HER2-positive breast cancer preferred the subcutaneous administration.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news